114 related articles for article (PubMed ID: 38466147)
1. Exploring the effect of Wuzhi capsule on the pharmacokinetics of regorafenib and its main metabolites in rat plasma using liquid chromatography-tandem mass spectrometry.
Zhu J; Zhong L; Song Y; Ding H; Xin W; Xu G; Fang L
J Sep Sci; 2024 Mar; 47(5):e2300923. PubMed ID: 38466147
[TBL] [Abstract][Full Text] [Related]
2. Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats.
Wei H; Tao X; Di P; Yang Y; Li J; Qian X; Feng J; Chen W
Drug Metab Dispos; 2013 Jul; 41(7):1398-403. PubMed ID: 23628674
[TBL] [Abstract][Full Text] [Related]
3. Validation of an LC-MS/MS method for quantitative analysis of the 5 bioactive components of Wuzhi capsule in human plasma samples.
Wei H; Miao H; Yun Y; Li J; Qian X; Wu R; Chen W
Ther Drug Monit; 2014 Dec; 36(6):781-8. PubMed ID: 25392942
[TBL] [Abstract][Full Text] [Related]
4. UPLC-MS/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies.
Cui Y; Li Y; Fan L; An J; Wang X; Fu R; Dong Z
J Pharm Biomed Anal; 2021 Nov; 206():114360. PubMed ID: 34508926
[TBL] [Abstract][Full Text] [Related]
5. Effect of hepar-protecting Wuzhi capsule on pharmacokinetics and dose-effect character of tacrolimus in healthy volunteers.
Teng F; Wang W; Zhang W; Qu J; Liu B; Chen J; Liu S; Li M; Chen W; Wei H
Biopharm Drug Dispos; 2022 Aug; 43(4):119-129. PubMed ID: 35180322
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction.
Huang S; Song W; Jiang S; Li Y; Wang M; Yang N; Zhu H
Chem Biol Interact; 2024 Mar; 391():110906. PubMed ID: 38340974
[TBL] [Abstract][Full Text] [Related]
7. Wuzhi capsule increased systemic exposure to methotrexate by inhibiting the expression of OAT1/3 and P-gp.
Fu R; Wang XN; Guo CH; Li Y; Ding CY; Li YJ; Dong ZJ
Ann Transl Med; 2021 May; 9(10):845. PubMed ID: 34164479
[TBL] [Abstract][Full Text] [Related]
8. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.
Cheng F; Li Q; Wang J; Zeng F; Zhang Y
J Clin Pharm Ther; 2021 Dec; 46(6):1636-1649. PubMed ID: 34342024
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.
Fu Q; Chen M; Hu S; McElroy CA; Mathijssen RH; Sparreboom A; Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1090():43-51. PubMed ID: 29783173
[TBL] [Abstract][Full Text] [Related]
10. Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high-dose cyclophosphamide-induced nephrotoxicity and neurotoxicity in rats.
Chen L; Xiong X; Hou X; Wei H; Zhai J; Xia T; Gong X; Gao S; Feng G; Tao X; Zhang F; Chen W
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):142-151. PubMed ID: 30793490
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Allard M; Khoudour N; Rousseau B; Joly C; Costentin C; Blanchet B; Tournigand C; Hulin A
J Pharm Biomed Anal; 2017 Aug; 142():42-48. PubMed ID: 28494338
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
Pang YY; Tan YL; Ho HK
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
[TBL] [Abstract][Full Text] [Related]
16. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
[TBL] [Abstract][Full Text] [Related]
17. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
18. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
19. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
